VIR Vir Biotechnology Inc.
Health Care, filed as VIR BIOTECHNOLOGY INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
- 1 exit
In 2026 Q3 David Witzke sold out of Vir Biotechnology.
Who owns VIR
Sorted by value, long equity only, as of 2026 Q3. Exits show their last held size.
| History | |||||
|---|---|---|---|---|---|
| David Witzke, Avidity Partners Management exited 2026 Q3 Last 2026 Q2 | Exit −0.85% | 519,300 | $5.3M | History |
Insider trades
Open-market buys and sales by VIR's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $7M sold by 6 insiders under 10b5-1 plans
-
Vanina De Verneuil EVP, General Counsel, Corp SecPlanned sale$27K 2,407 shares at $11.10 2.1% of stakeTraded Nov 3 Filed Nov 4
-
Janet Napolitano DirectorPlanned sale$30K 3,200 shares at $9.45 13% of stakeTraded Jun 1 Filed Jun 2
-
Brent Sabatini SVP, Chief Accounting OfficerPlanned sale$3,582 379 shares at $9.45 0.6% of stakeTraded Jun 1 Filed Jun 2
-
Vicki L. Sato DirectorPlanned sale$221K 22,000 shares at $10.05 2% of stakeTraded May 1 Filed May 4
-
Vicki L. Sato DirectorPlanned sale$200K 22,000 shares at $9.07 2% of stakeTraded Apr 1 Filed Apr 2
-
Brent Sabatini SVP, Chief Accounting OfficerPlanned sale$70K 7,711 shares at $9.12 11% of stakeTraded Mar 23 Filed Mar 24
-
Vicki L. Sato DirectorPlanned sale$209K 22,000 shares at $9.51 1.9% of stakeTraded Mar 2 Filed Mar 3
-
Vicki L. Sato DirectorPlanned sale$413K 42,377 shares at $9.75 3.6% of stakeTraded Feb 24 Filed Feb 26
-
Mark Eisner EVP and Chief Medical OfficerPlanned sale$19K 1,889 shares at $9.82 1.2% of stakeTraded Feb 25 Filed Feb 26
-
Vanina De Verneuil EVP, General Counsel, Corp SecPlanned sale$135K 13,700 shares at $9.82 11% of stakeTraded Feb 25 Filed Feb 26
-
Vicki L. Sato DirectorPlanned sale$170K 22,000 shares at $7.71 1.9% of stakeTraded Feb 2 Filed Feb 3
-
Vicki L. Sato DirectorPlanned sale$130K 22,000 shares at $5.93 1.9% of stakeTraded Jan 2 Filed Jan 5
-
SVF Endurance (Cayman) Ltd 10% owner, +2 joint filersPlanned sale$1.1M 191,854 shares at $5.98 1.4% of stakeTraded Dec 1, 2025 Filed Dec 3, 2025
-
Vicki L. Sato DirectorPlanned sale$132K 22,000 shares at $6.00 1.8% of stakeTraded Dec 1, 2025 Filed Dec 2, 2025
-
SVF Endurance (Cayman) Ltd 10% owner, +2 joint filersPlanned sale$1.2M 189,431 shares at $6.41 1.3% of stakeTraded Nov 26–28 Filed Dec 1, 2025
Also filed in the last 12 months, not counted as buying or selling: 17 stock grants, 13 sales to cover taxes, 6 other transactions, and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 24 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 3.02,8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02,5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc |
No filings match this filter.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon